PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjcrInstructions for authorsCurrent ToCBMJ Case Reports
 
BMJ Case Rep. 2010; 2010: bcr0520102975.
Published online Oct 21, 2010. doi:  10.1136/bcr.05.2010.2975
PMCID: PMC3027573
Unexpected outcome (positive or negative) including adverse drug reactions
Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester
Soley Bayraktar,1 Belline Morency,2 and Maricer P Escalón2
1Department of Hematology/Oncology, MD Anderson Cancer Center, Houston, Texas, USA
2Department of Hematology/Oncology, University of Miami, Miami, Florida, USA
Correspondence to Soley Bayraktar, sbayraktar/at/mdanderson.org
Abstract
We report a case of a 25-year-old woman with chronic myeloid leukaemia who was randomised to dasatinib 100 mg orally daily in a clinical trial. The patient was advised to avoid pregnancy while on treatment due to its teratogenic potential. Five months later, the patient was found to be 6 weeks pregnant. Once pregnancy was confirmed, dasatinib was immediately stopped and the patient was taken off the trial. She was managed conservatively during the remainder of her pregnancy with close observation only. She delivered a healthy infant at 37 weeks' gestation without any documented birth defects. Dasatinib has been shown in animal studies to cause fetal toxicities, but the effect of exposure during conception and pregnancy in humans is not known. We provide a full report of a successful pregnancy in a patient who was exposed to dasatinib during the first trimester; we also give a brief literature review.
Articles from BMJ Case Reports are provided here courtesy of
BMJ Group